

MagicTouch PTA

3 years

Sustained safety & clinical efficacy results of XTOSI: A Sirolimus DCB study

Study PI - Prof. Edward Choke

Experience The Magic.



XTOSI - First Ever Trial to release 3 years data of Sirolimus DCB in PAD

showcasing sustained safety & clinical efficacy results in the challenging cohort of high-risk CLTI patients, using MagicTouch PTA - Sirolimus Drug Coated Balloon.

84.4%

Freedom From TLR¹

86.1%

Freedom From Major Amputation¹

63.3%

Amputation Free Survival¹

100%
HEALING*

*Ulcer free status in remaining survivors with intact limbs

CM Concept Medical

Scan to Read Abstract



www.conceptmedical.com | info@conceptmedical.com

[f](#) [t](#) [@](#) [in](#) /conceptmedicals

Reference:

1. doi: 10.1016/j.avsg.2023.12.096. 03 April 2024.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device. For restricted use only in countries where product registered with applicable health authorities. Approved by US FDA for use in Clinical Trials only.